Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Adolor aims to advance ADL-2-1294 into clinical trials

April 26, 1996

BMS antimigraine agent poised to enter clinical trials

April 26, 1996

NPC-18688 displays long-lasting antihyperalgesic effects in rodents

April 26, 1996

SKB claims morphinoid derivatives

April 26, 1996

OT-7100, Otsuka's new analgesic for peripheral pain

April 26, 1996

Combined thrombolytic/neuroprotective agents more effective in treating stroke

April 19, 1996

Nerve growth synthesis inducers produce neuroprotective effects

April 19, 1996

SKB reports calcium antagonists for stroke

April 19, 1996

New Takeda compounds suppress increased vascular permeability

April 19, 1996

Lilly reports cannabinoid receptor antagonists

April 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...